COSCIENS Biopharma (CSCI) 6-K/A 4 Aug 22 Current report (foreign) (amended) Financial data

Cover

Cover	6 Months Ended
	Jun. 30, 2022
Cover [Abstract]
Document Type	6-K/A
Amendment Flag	true
Amendment Description	This Amendment No. 1 to the 6-K of Aeterna Zentaris Inc. (the “Company”) which was filed with the Securities and Exchange Commission on August 03, 2022. The Company is filing this Amendment No. 1 solely to file Exhibit 101, which was not included in the Original 6-K, in accordance with Rule 405 of Regulation S-T. Exhibit 101 contains interactive data files in Inline eXtensible Business Reporting Language (iXBRL).
Document Period End Date	Jun. 30, 2022
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-38064
Entity Registrant Name	Aeterna Zentaris Inc.
Entity Central Index Key	0001113423
Entity Address, Address Line One	c/o Norton Rose Fulbright Canada, LLP
Entity Address, Address Line Two	222 Bay Street
Entity Address, Address Line Three	Suite 3000, PO Box 53
Entity Address, City or Town	Toronto
Entity Address, Country	CA
Entity Address, Postal Zip Code	M5K 1E7

Condensed Interim Consolidated

Condensed Interim Consolidated Statements of Financial Position - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 58,157	$ 65,300
Trade and other receivables (note 4)	907	1,314
Inventory	261	73
Income taxes receivable	1,389	2,361
Prepaid expenses and other current assets (note 5)	2,459	1,772
Total current assets	63,173	70,820
Restricted cash equivalents	314	335
Right of use assets	114	150
Property, plant and equipment	42	42
Other non-current assets	122
Identifiable intangible assets	573	625
Goodwill	7,487	8,130
Total Assets	71,825	80,102
Current liabilities
Payables and accrued liabilities (note 6)	2,635	2,672
Current portion of provisions	27	34
Income taxes payable	105	115
Current portion of deferred revenues (note 3)	3,534	4,815
Current portion of lease liabilities	106	130
Total current liabilities	6,407	7,766
Deferred revenues (note 3)	2,617	1,493
Deferred gain	90	98
Lease liabilities	16	31
Employee future benefits (note 7)	8,188	17,485
Provisions	213	243
Total liabilities	17,531	27,116
SHAREHOLDERS’ EQUITY
Share capital (note 8)	293,410	293,410
Warrants (note 8)	5,085	5,085
Other capital (note 8)	89,848	89,788
Deficit	(333,450)	(334,619)
Accumulated other comprehensive loss (“AOCI”)	(599)	(678)
Total shareholders’ equity	54,294	52,986
Total liabilities and shareholders’ equity	$ 71,825	$ 80,102

Condensed Interim Consolidate_2

Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Issued capital [member]	Warrants [member]	Other equity interest [member]	Retained earnings [member]	Accumulated Other Comprehensive Loss Income [member]	Total
Beginning balance at Dec. 31, 2020	$ 235,008	$ 12,402	$ 89,505	$ (322,659)	$ (1,045)	$ 13,211
Beginning balance, shares at Dec. 31, 2020	2,507,145
IfrsStatementLineItems [Line Items]
Net loss (as restated note1)				(3,542)		(3,542)
Foreign currency translation adjustments					421	421
Actuarial gain on defined benefit plans				(86)		(86)
Comprehensive loss				(3,628)	421	(3,207)
Share-based compensation costs			273			273
Issuance of common shares, net of transaction costs	$ 29,082	1,897				30,979
Issuance of common shares, net of transaction costs, shares	943,448
Exercise of warrants	$ 29,769	(9,728)				20,041
Exercise of warrants, shares	1,400,447
Transfer of warrant issuance costs upon 2021 exercise of warrants (note 8)	$ (532)	532
Exercise of deferred share units (note 8)	$ 20		(28)			(8)
Exercise of deferred share units (note 8), shares	840
Ending balance at Jun. 30, 2021	$ 293,347	5,103	89,750	(326,287)	(624)	61,289
Ending balance, shares at Jun. 30, 2021	4,851,880
Beginning balance at Dec. 31, 2021	$ 293,410	5,085	89,788	(334,619)	(678)	52,986
Beginning balance, shares at Dec. 31, 2021	4,855,876
IfrsStatementLineItems [Line Items]
Net loss (as restated note1)				(6,856)		(6,856)
Foreign currency translation adjustments					79	79
Actuarial gain on defined benefit plans				8,025		8,025
Comprehensive loss				1,169	79	1,248
Share-based compensation costs			60			60
Ending balance at Jun. 30, 2022	$ 293,410	$ 5,085	$ 89,848	$ (333,450)	$ (599)	$ 54,294
Ending balance, shares at Jun. 30, 2022	4,855,876

Condensed Interim Consolidate_3

Condensed Interim Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues (note 3)
License fees	$ (206)	$ 492	$ 226	$ 1,016
Development Services	(77)	1,030	889	2,125
Product sales			57
Royalties	24	19	43	27
Supply chain	37	43	80	84
Total revenues	(222)	1,584	1,295	3,252
Operating expenses
Cost of sales	13	12	92	41
Research and development expenses	2,398	1,768	4,788	3,226
General and administrative expenses	1,781	1,645	3,339	2,909
Selling expenses	302	318	605	564
Total operating expenses	4,494	3,743	8,824	6,740
Loss from operations	(4,716)	(2,159)	(7,529)	(3,488)
Gain (loss) due to changes in foreign currency exchange rates	502	82	676	(166)
Other finance costs	(2)	(7)	(3)	(17)
Net finance income (costs)	500	75	673	(183)
Loss before income taxes	(4,216)	(2,084)	(6,856)	(3,671)
Income tax recovery				129
Net loss	(4,216)	(2,084)	(6,856)	(3,542)
Items that may be reclassified subsequently to profit or loss:
Foreign currency translation adjustments	42	(126)	79	421
Items that will not be reclassified to profit or loss:
Actuarial gain (loss) on defined benefit plans (note 7)	5,276	(968)	8,025	(86)
Comprehensive income (loss)	$ 1,102	$ (3,178)	$ 1,248	$ (3,207)
Net loss per share [basic and diluted]	$ (0.87)	$ (0.43)	$ (1.41)	$ (0.82)
Weighted average number of shares outstanding (note 11):
Basic	4,855,876	4,848,129	4,855,876	4,335,821
Diluted	4,855,876	4,848,129	4,855,876	4,335,821

Condensed Interim Consolidate_4

Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities
Net loss for the period	$ (4,216)	$ (2,084)	$ (6,856)	$ (3,542)
Items not affecting cash and cash equivalents:
Provision	7	1	5	20
Depreciation and amortization	35	36	71	72
Share-based compensation costs	33	260	60	273
Employee future benefits (note 7)	98	50	197	99
Amortization of deferred revenues	124	(492)	(704)	(1,016)
Foreign exchange on items denominated in foreign currencies	(513)	(54)	(687)	212
Gain on disposal of property, plant and equipment		(1)		(1)
Other non-cash items	495	(114)	509	(85)
Interest accretion on lease liabilities		1		3
Payment (refund) of income taxes	(51)	(517)	830	(1,641)
Other asset		(82)		(82)
Changes in operating assets and liabilities (note 9)	(862)	(639)	264	1,008
Net cash used in operating activities	(4,850)	(3,635)	(6,311)	(4,680)
Cash flows from financing activities
Issuance of common shares (note 8)				34,200
Transaction costs (note 8)				(3,221)
Proceeds from exercise of warrants (note 8)		55		20,041
Payments on lease liabilities	(34)	(31)	(68)	(63)
Net cash provided by (used in) financing activities	(34)	24	(68)	50,957
Cash flows from investing activities
Proceeds from disposal of property, plant and equipment		1		1
Purchase of intangible assets				(490)
Purchase of property and equipment	(42)	(3)	(48)	(20)
Net cash “used in” provided by investing activities	(42)	(2)	(48)	(509)
Effect of exchange rate changes on cash and cash equivalents	(513)	110	(716)	(171)
Net change in cash and cash equivalents	(5,439)	(3,503)	(7,143)	45,597
Cash and cash equivalents – Beginning of period	63,596	73,371	65,300	24,271
Cash and cash equivalents – End of period	$ 58,157	$ 69,868	$ 58,157	$ 69,868

Business overview

Business overview	6 Months Ended
	Jun. 30, 2022
Disclosure of detailed information about business combination [abstract]
Business overview	1. Business overview Summary of business Aeterna Zentaris (the “Company” or “Aeterna”) is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen™ (macimorelin), is the first and only U.S. Food and Drug Administration (“FDA”) and European Medicines Agency-approved oral test indicated for the diagnosis of patients with adult growth hormone deficiency (“AGHD”). Macrilen™ is currently marketed in the US through a license agreement (the “Novo Amendment”) between the Company and Novo Nordisk Health Care AG (“Novo”) and in the United Kingdom and Europe through a license agreement with Consilient Healthcare Inc (“Consilient” or “CH”) under the trade name of Ghryvelin®. The Company is also dedicated to the development of therapeutic assets and has recently taken steps to establish a pre-clinical pipeline to potentially address unmet medical needs across a number of indications with a focus on rare or orphan indications and with the potential for pediatric use. These unaudited condensed interim consolidated financial statements were approved by the Board of Directors (the “Board”) on August 3, 2022. Basis of presentation These unaudited condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”) applicable to the preparation of interim financial statements, including IAS 34, Interim Financial Reporting. These unaudited condensed interim consolidated financial statements should be read in conjunction with the Company’s annual consolidated financial statements as at and for the year ended December 31, 2021. The accounting policies in these condensed interim consolidated financial statements are consistent with those presented in the Company’s annual consolidated financial statements, with the exception of the Company’s policy with respect to the government assistance which is as follows: Government assistance Amounts received or receivable resulting from government assistance programs, including grants and refundable investment tax credits for research and development, are accounted for in accordance with IAS 20 NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT JUNE 30, 2022 AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted) COVID-19 & Russia and Ukraine conflict The rise in COVID-19 variants has caused delays in site initiation and patient enrollment in our DETECT-trial and may be impacting sales activities for Macrilen™ in the US. Further, the continuation of the COVID-19 pandemic and the Russia/Ukraine conflict may also cause some patients to be unwilling to enroll in our trials or be unable to comply with clinical trial protocols if such events impede patient movement or interrupt healthcare services, both of which would delay our ability to conduct clinical trials or release clinical trial results on a timely basis and could delay our ability to obtain regulatory approval and commercialize our product candidates. For the period ended June 30, 2022, the Company assessed the impact of the uncertainties around the COVID-19 pandemic and the Russia/Ukraine conflict on its judgments, estimates, accounting policies and amounts recognized in these unaudited condensed interim consolidated financial statements and determined that no adjustments were required to the carrying value of assets and liabilities. Management determined that the recruitment for the DETECT-trial may now continue until later into 2023 compared to the end of the 2022 year as anticipated at the end of the previous fiscal year. As such, amounts related to deferred revenue have been reclassified from current to long-term to reflect the revised timeline. We are currently assessing with Novo the impact on timelines and study cost. Preliminary indications are that the delays associated with COVID-19 and the Russia/Ukraine conflict will result in additional costs to the program. As such, this resulted in reversal of revenue in both the license fees and development services for the quarter and in negative revenues of $ 0.2 0.1 The Company will continue to monitor the impact of the development of the COVID-19 pandemic and Russia/Ukraine conflict in further reporting periods. Actual results could differ from these estimates, and such differences may be material. Restatement of comparative period figures At the end of the prior fiscal year 2021, the Company restated its previously reported condensed consolidated interim financial statements for the three-month period ended March 31, 2021 and the three-month and six-month periods ended June 30, 2021 and three-month and nine-month periods ended September 30, 2021 with respect to the recognition of revenue for the Novo Amendment, signed in November 2020. During the fourth quarter of 2021, management reassessed the classification of the development activities associated with the DETECT-trial and concluded that subsequent to the Novo Amendment, the parties no longer shared joint control of these activities and, as such, these development activities no longer met the definition of a joint operation, as defined in IFRS 11 IFRS 15 NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT JUNE 30, 2022 AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted) The condensed interim consolidated financial statements were not adjusted and refiled at the time of discovery of the error, rather the comparatives are being corrected now with the filing of the interim financials for the period ended June 30, 2022. The impacts of the June 30, 2021 restatements are as follows (amounts in thousands, except for basic and diluted loss per share): Summary of Detailed Information about Restatement Explanatory Previously Effect of reported restatement Amended $ $ $ Consolidated interim statement of loss and comprehensive loss for the three-month period ended June 30, 2021 License fees 537 (45 ) 492 Development service revenues — 1,030 1,030 Research and development expenses 738 1,030 1,768 Net loss (2,039 ) (45 ) (2,084 ) Total comprehensive loss (3,133 ) (45 ) (3,178 ) Basic and diluted loss per share (0.42 ) (0.01 ) (0.43 ) Consolidated interim statement of loss and comprehensive loss for the six-month period ended June 30, 2021 License fees 1,074 (58 ) 1,016 Development service revenues — 2,125 2,125 Research and development expenses 1,101 2,125 3,226 Net loss (3,484 ) (58 ) (3,542 ) Total comprehensive loss (3,149 ) (58 ) (3,207 ) Basic and diluted loss per share (0.72 ) (0.01 ) (0.82 ) Consolidated interim statement of financial position as of June 30, 2021 Prepaid expenses and other current assets 3,308 1,067 4,375 Current portion of deferred revenues 2,125 1,111 3,236 Deficit (326,229 ) (58 ) (326,287 )

Critical accounting estimates a

Critical accounting estimates and judgements	6 Months Ended
	Jun. 30, 2022
Critical accounting estimates and judgements	2. Critical accounting estimates and judgements The preparation of condensed interim consolidated financial statements in accordance with IFRS requires management to make judgments, estimates and assumptions that affect the reported amounts of the Company’s assets, liabilities, revenues, expenses and related disclosures. Judgments, estimates and assumptions are based on historical experience, expectations, current trends and other factors that management believes to be relevant at the time at which the Company’s condensed interim consolidated financial statements are prepared. Management reviews, on a regular basis, the Company’s accounting policies, assumptions, estimates and judgments in order to ensure that the condensed interim consolidated financial statements are presented fairly and in accordance with IFRS applicable to interim financial statements. Critical accounting estimates and assumptions, as well as critical judgments used in applying accounting policies in the preparation of the Company’s condensed interim consolidated financial statements, were the same as those applied to the Company’s annual consolidated financial statements as at and for the year ended December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, and 2020. NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT JUNE 30, 2022 AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted)

License and supply arrangements

License and supply arrangements	6 Months Ended
	Jun. 30, 2022
License and supply arrangements	3. License and supply arrangements On November 16, 2020, the Company, through AEZS Germany, entered into Novo Amendment of its existing License Agreement with Novo related to the development and commercialization of macimorelin. The Company earns license fees, product sales, royalties and supply chain revenue, in addition to development service revenue from conducting the Study P02, from Novo. In June 2020, the Company entered into an exclusive distribution and quality agreement with MegaPharm Ltd. (“MegaPharm”) for the commercialization in Israel and in the Palestinian Authority of macimorelin to be used in the diagnosis of patients with adult growth hormone deficiency and in clinical development for the diagnosis of pediatric growth hormone deficiency (the “MegaPharm Agreement”). As of June 30, 2022, there have been no products supplied under this agreement. On December 7, 2020, the Company entered into an exclusive licensing agreement with “CH” for the commercialization of macimorelin in the European Economic Area and the United Kingdom (the “CH License Agreement”). The Company earns licenses fees and product sale revenue from CH. The Company and NK Meditech Limited (“NK”) entered into a licensing agreement, effective November 30, 2021 and pursuant to which the Company granted to NK the exclusive right to commercialize (including marketing, selling and offering to sell) macimorelin in the Republic of Korea (the “ROK”) and as applicable, in the Democratic People’s Republic of Korea (“DPRK”) to the extent NK is allowed to use the aforementioned licensed rights in the latter (“NK License Agreement”). As of June 30, 2022, there have been no products supplied under this agreement. The following table provides a summary of deferred revenue balances: Summary of Revenue Explanatory June 30, 2022 Current Non-Current Total $ $ $ Novo Amendment 3,523 1,050 4,573 CH License Agreement 11 1,440 1,451 NK License Agreement — 127 127 Total 3,534 2,617 6,151 December 31, 2021 Current Non-Current Total $ $ $ Novo Amendment 4,791 23 4,814 CH License Agreement 24 1,334 1,358 NK License Agreement — 136 136 Total 4,815 1,493 6,308 NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT JUNE 30, 2022 AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted)

Trade and other receivables

Trade and other receivables	6 Months Ended
	Jun. 30, 2022
Trade and other receivables	4. Trade and other receivables Summary of Detailed Trade and Other Receivables Explanatory June 30, 2022 December 31, 2021 $ $ Trade accounts receivable (net of expected credit losses of $ 55 55 490 877 Value-added tax 182 372 Grant receivable 179 — Other 56 65 Trade and other receivables 907 1,314 In March 2022, the Company was awarded a monetary subsidy with respect to two pre-clinical programs—namely, the Company’s development of an oral vaccine against infections with SARS-CoV-2 and the development of a product candidate for the treatment of neuromyelitis optica. The subsidy was awarded pursuant to the provisions of the German Act on Tax Incentives for Research and Development, which provides direct reimbursement of certain qualifying R&D expenditures to eligible entities. The CoV-2 grant is related to R&D expenditures incurred in 2021 and during the first half year of 2022. The Neuromyelitis Optica grant is related to expenditures incurred in 2021 and during the first half of 2022.

Prepaid expenses and other curr

Prepaid expenses and other current assets	6 Months Ended
	Jun. 30, 2022
Prepaid expenses and other current assets	5. Prepaid expenses and other current assets Summary of Prepaid Expenses and Other Current Assets Explanatory June 30, 2022 December 31, 2021 $ $ Prepaid insurance 1,259 421 Prepaid research and development 1,111 1,329 Other 89 22 Prepaid expenses and other current assets 2,459 1,772

Payables and accrued liabilitie

Payables and accrued liabilities	6 Months Ended
	Jun. 30, 2022
Payables and accrued liabilities	6. Payables and accrued liabilities Summary of Detailed Information about Payables and Accrued Liabilities Explanatory June 30, 2022 December 31, 2021 $ $ Trade accounts payable 938 934 Salaries, employment taxes and benefits 120 531 Accrued research and development costs 995 596 Other accrued liabilities 582 611 Payables and accrued liabilities 2,635 2,672 NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT JUNE 30, 2022 AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted)

Employee future benefits

Employee future benefits	6 Months Ended
	Jun. 30, 2022
Employee future benefits	7. Employee future benefits The change in the Company’s accrued benefit obligations is summarized as follows: Summary of Net Defined Benefit Liability Asset Explanatory Six months ended June 30, 2022 Year ended December 31, 2021 Pension benefit plans Other Total Total $ $ $ $ Change in plan liabilities Balances – Beginning of the period 29,313 99 29,412 15,435 Current service cost 33 5 38 65 Interest cost 149 — 149 88 Employee Contributions 7 — 7 — Actuarial gain arising from changes in financial assumptions (9,802 ) — (9,802 ) (1,130 ) Past service cost associated with multi-employer plan — — — 16,137 Actuarial loss arising from change in current assumptions on funding of future pension increases — — — 556 Benefits paid (344 ) (1 ) (345 ) (511 ) Impact of foreign exchange rate changes (2,098 ) (8 ) (2,106 ) (1,228 ) Balances – End of the period 17,258 95 17,353 29,412 Change in plan assets Balances – Beginning of the period 11,927 — 11,927 — Presentation of plan assets as of December 31, 2021 — — — 11,963 Remeasurement of plan assets (1,777 ) — (1,777 ) — Employer contributions 32 — 32 — Employee contributions 7 — 7 — Benefits paid (122 ) — (122 ) — Impact of foreign exchange rate changes (902 ) — (902 ) (36 ) Balances – End of the period 9,165 9,165 11,927 Net liability of the unfunded plans 7,574 95 7,669 12,749 Net liability of the funded plans 519 — 519 4,736 Net amount recognized as Employee future benefits 8,093 95 8,188 17,485 Amounts recognized: In net loss 181 6 187 (153 ) In other comprehensive loss (9,221 ) (8 ) (9,229 ) 2,408 The calculation of the pension benefit obligation is sensitive to the discount rate assumption. Discount rates were 1.1% 3.25% NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT JUNE 30, 2022 AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted)

Share capital, warrants and oth

Share capital, warrants and other capital	6 Months Ended
	Jun. 30, 2022
Disclosure of classes of share capital [abstract]
Share capital, warrants and other capital	8. Share capital, warrants and other capital The Company has an unlimited number of authorized common shares (being voting and participating shares) with no par value, as well as an unlimited number of preferred, first and second ranking shares, issuable in series, with rights and privileges specific to each class, with no par value. 2021 On February 19, 2021, the Company completed an underwritten public offering of 820,390 36.25 29,739 2,837 123,058 36.25 57,427 45.3125 February 17, 2026 On February 22, 2021, the underwriter exercised the Underwriter Option in full and received 123,058 4,461 8,614 Aggregate gross proceeds received in connection with the February 2021 Financing totaled $ 34,200 3,221 1,897 The table presented below shows the inputs and assumptions applied to the Black-Scholes option pricing model in order to determine the fair value of these Placement agent warrants: Summary of Fair Value of Warrants Assumptions Explanatory Number of equivalent shares Market value per share price Weighted average exercise price Risk-free annual interest rate Expected volatility Expected life (years) Expected dividend yield ($) ($) (i) (ii) (iii) (iv) February 2021 Placement agent warrants – public offering 57,427 37.00 45.31 0.58734 % 119.18 % 4.99 0.00 % February 2021 Placement agent warrants – Underwriter Option 8,614 37.00 45.31 0.58544 % 119.57 % 4.98 0.00 % (i) Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the warrants. (ii) Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the warrants. (iii) Based upon time to expiry from the issuance date. (iv) The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future. NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT JUNE 30, 2022 AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted) During the six-month period ended June 30, 2021, warrants were exercised as follows:: Summary of Warrants Exercise Transactions Explanatory Warrants exercised (number of underlying common shares) Exercise Price Aggregate proceeds to the Company September 2019 Investor warrants 80,000 $ 41.25 $ 3,300 February 2020 Investor warrants 69,565 30.00 2,087 July 2020 Investor warrants 841,822 11.25 9,471 July 2020 Placement Agent warrants 74,667 14.0625 1,050 August 2020 Investor warrants 303,595 11.75 3,567 August 2020 Placement Agent warrants 34,798 17.6015625 612 1,404,447 $ 20,087 Other capital Summary of Number and Weighted Average Exercise Prices of Share Options Explanatory Six months ended June 30, 2022 Stock options Weighted average exercise DSUs (Number) ($) (Number) Balance – January 1, 2022 43,455 22.00 16,920 Granted 2,000 9.00 — Expired — — — Exercised — — — Balance – June 30, 2022 45,455 21.25 16,920 Year ended December 31, 2021 Stock options Weighted average exercise DSUs (Number) ($) (Number) Balance – January 1, 2021 20,256 36.00 6,920 Granted 23,200 10.50 11,200 Expired (1 ) 14,756.25 — Exercised — — (1,200 ) Balance – December 31, 2021 43,455 22.00 16,920 NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT JUNE 30, 2022 AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted) Fair value input assumptions for US dollar stock option grants The table below shows the assumptions, or weighted average parameters, applied to the Black-Scholes option pricing model in order to determine share-based compensation costs over the life of the awards. Summary of Assumptions to Determine Share-based Compensation Costs Six Months Ended Year Ended June 30, December 31 2022 2021 Expected dividend yield (a) 0.00 % 0.00 % Expected volatility (b) 115.80 % 115.80 % Risk-free annual interest rate (c) 1.23 % 1.23 % Expected life (years) (d) 5.71 5.71 Weighted average share price $ 0.42 $ 0.42 Weighted average exercise price $ 0.42 $ 0.42 Weighted average grant date fair value $ 0.35 $ 0.35 (a) The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future. (b) Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the stock options, as well as on future expectations. (c) Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the stock options. (d) Based upon historical data related to the exercise of stock options, on post-vesting employment terminations and on future expectations related to exercise behavior.

Supplemental disclosure of cash

Supplemental disclosure of cash flow information	6 Months Ended
	Jun. 30, 2022
Supplemental disclosure of cash flow information	9. Supplemental disclosure of cash flow information Summary of Changes in Operating Assets and Liabilities Explanatory Three months ended Six months ended June 30, June 30, 2022 2021 2022 2021 $ $ $ $ Changes in operating assets and liabilities: Trade and other receivables (255 ) (547 ) 220 103 Inventory — 1 (206 ) (39 ) Prepaid expenses and other current assets (1,471 ) 408 (759 ) 315 Payables and accrued liabilities (40 ) (430 ) 119 (315 ) Taxes payable — — — (129 ) Deferred revenues 1,001 3 1,008 1,230 Employee future benefits (97 ) (74 ) (118 ) (157 ) Changes in operating assets and liabilities (862 ) (639 ) 264 1,008 NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT JUNE 30, 2022 AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted)

Segment information

Segment information	6 Months Ended
	Jun. 30, 2022
Segment information	10. Segment information The Company operates in a single operating segment, being the biopharmaceutical segment.

Net loss per share

Net loss per share	6 Months Ended
	Jun. 30, 2022
Net loss per share	11. Net loss per share The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders. Summary of Earnings per Share Explanatory Three months ended Six months ended June 30, June 30, 2022 2021 2022 2021 $ $ $ $ Net loss (4,216 ) (2,084 ) (6,856 ) (3,542 ) Basic weighted average number of shares outstanding 4,855,876 4,848,129 4,855,876 4,335,821 Net loss income per share (basic) (0.87 ) (0.43 ) (1.41 ) (0.82 ) Dilutive effect of stock options and DSUs — — — — Dilutive effect of warrants — — — — Diluted weighted average number of shares outstanding 4,855,876 4,848,129 4,855,876 4,335,821 Net loss per share (diluted) (0.87 ) (0.43 ) (1.41 ) (0.82 ) Items excluded from the calculation of diluted net loss per share because the exercise price was greater than the average market price of the common shares or due to their anti-dilutive effect Stock options and DSUs 62,375 37,176 62,375 37,176 Warrants 457,649 461,649 457,649 461,649 Net loss per share is calculated by dividing net loss by the weighted average number of shares outstanding during the relevant period. Diluted weighted average number of shares reflects the dilutive effect of equity instruments, such as any “in the money” stock options, DSUs and warrants. In periods with reported net losses, all stock options and warrants are deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal, and thus “in the money” stock options and warrants have not been included in the computation of net loss per share because to do so would be anti-dilutive.

Commitments

Commitments	6 Months Ended
	Jun. 30, 2022
Commitments	12. Commitments Summary of Finance Lease and Operating Lease by Lessee Explanatory Service and manufacturing R&D contracts TOTAL $ $ $ Less than 1 year 5,015 2,090 7,105 1 - 3 years 938 776 1,714 4 - 5 years 47 — 47 More than 5 years — — — Total 6,000 2,866 8,866 The Company executed various agreements including in-licensing and similar arrangements with development partners. Such agreements may require the Company to make payments on achievement of stages of development, launch or revenue milestones, although the Company generally has the right to terminate these agreements at no penalty. NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS AT JUNE 30, 2022 AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2022 AND 2021 (amounts in thousands of US dollars, except share and per share data and as otherwise noted) Based on the closing exchange rates at June 30, 2022, the Company expects to pay $ 9,050 6.5 1.2 39,302 27.6 1.3 9,000 Summary of Research and Development and Revenue Related Milestone Payments Explanatory Future potential R&D milestone payments Future potential revenue milestone payments TOTAL $ $ $ Less than 1 year 26 — 26 1 - 3 years 204 — 204 4 - 5 years 1,990 — 1,990 More than 5 years 6,830 39,302 46,132 Total 9,050 39,302 48,352 The future payments that are disclosed represent contract payments and are not discounted and are not risk-adjusted. The development of any pharmaceutical product candidates is a complex and risky process that may fail at any stage in the development process due to a number of factors. The timing of the payments is based on the Company’s current best estimate of achievement of the relevant milestone.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events	13. Subsequent Events Reverse Stock Split On July 15, 2022, the Company’s shareholders and board of directors approved an amendment to the Company’s articles of amendment to effect a 1-for-25 reverse stock split of the Company’s common shares, DSU and Warrants. The Company’s outstanding stock options were also adjusted to reflect the 1-for-25 reverse stock split of the Company’s common shares. Accordingly, all common shares, DSU and Warrants, stock options and per share amounts in these consolidated financial statements have been retroactively adjusted for all periods presented to give effect to the reverse stock split. Outstanding stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The reverse stock split was effected in the markets on July 21,2022.

Business overview (Tables)

Business overview (Tables)	6 Months Ended
	Jun. 30, 2022
Disclosure of detailed information about business combination [abstract]
Summary of Detailed Information about Restatement Explanatory	Summary of Detailed Information about Restatement Explanatory Previously Effect of reported restatement Amended $ $ $ Consolidated interim statement of loss and comprehensive loss for the three-month period ended June 30, 2021 License fees 537 (45 ) 492 Development service revenues — 1,030 1,030 Research and development expenses 738 1,030 1,768 Net loss (2,039 ) (45 ) (2,084 ) Total comprehensive loss (3,133 ) (45 ) (3,178 ) Basic and diluted loss per share (0.42 ) (0.01 ) (0.43 ) Consolidated interim statement of loss and comprehensive loss for the six-month period ended June 30, 2021 License fees 1,074 (58 ) 1,016 Development service revenues — 2,125 2,125 Research and development expenses 1,101 2,125 3,226 Net loss (3,484 ) (58 ) (3,542 ) Total comprehensive loss (3,149 ) (58 ) (3,207 ) Basic and diluted loss per share (0.72 ) (0.01 ) (0.82 ) Consolidated interim statement of financial position as of June 30, 2021 Prepaid expenses and other current assets 3,308 1,067 4,375 Current portion of deferred revenues 2,125 1,111 3,236 Deficit (326,229 ) (58 ) (326,287 )

License and supply arrangemen_2

License and supply arrangements (Tables)	6 Months Ended
	Jun. 30, 2022
Summary of Revenue Explanatory	The following table provides a summary of deferred revenue balances: Summary of Revenue Explanatory June 30, 2022 Current Non-Current Total $ $ $ Novo Amendment 3,523 1,050 4,573 CH License Agreement 11 1,440 1,451 NK License Agreement — 127 127 Total 3,534 2,617 6,151 December 31, 2021 Current Non-Current Total $ $ $ Novo Amendment 4,791 23 4,814 CH License Agreement 24 1,334 1,358 NK License Agreement — 136 136 Total 4,815 1,493 6,308

Trade and other receivables (Ta

Trade and other receivables (Tables)	6 Months Ended
	Jun. 30, 2022
Summary of Detailed Trade and Other Receivables Explanatory	Summary of Detailed Trade and Other Receivables Explanatory June 30, 2022 December 31, 2021 $ $ Trade accounts receivable (net of expected credit losses of $ 55 55 490 877 Value-added tax 182 372 Grant receivable 179 — Other 56 65 Trade and other receivables 907 1,314

Prepaid expenses and other cu_2

Prepaid expenses and other current assets (Tables)	6 Months Ended
	Jun. 30, 2022
Summary of Prepaid Expenses and Other Current Assets Explanatory	Summary of Prepaid Expenses and Other Current Assets Explanatory June 30, 2022 December 31, 2021 $ $ Prepaid insurance 1,259 421 Prepaid research and development 1,111 1,329 Other 89 22 Prepaid expenses and other current assets 2,459 1,772

Payables and accrued liabilit_2

Payables and accrued liabilities (Tables)	6 Months Ended
	Jun. 30, 2022
Summary of Detailed Information about Payables and Accrued Liabilities Explanatory	Summary of Detailed Information about Payables and Accrued Liabilities Explanatory June 30, 2022 December 31, 2021 $ $ Trade accounts payable 938 934 Salaries, employment taxes and benefits 120 531 Accrued research and development costs 995 596 Other accrued liabilities 582 611 Payables and accrued liabilities 2,635 2,672

Employee future benefits (Table

Employee future benefits (Tables)	6 Months Ended
	Jun. 30, 2022
Summary of Net Defined Benefit Liability Asset Explanatory	The change in the Company’s accrued benefit obligations is summarized as follows: Summary of Net Defined Benefit Liability Asset Explanatory Six months ended June 30, 2022 Year ended December 31, 2021 Pension benefit plans Other Total Total $ $ $ $ Change in plan liabilities Balances – Beginning of the period 29,313 99 29,412 15,435 Current service cost 33 5 38 65 Interest cost 149 — 149 88 Employee Contributions 7 — 7 — Actuarial gain arising from changes in financial assumptions (9,802 ) — (9,802 ) (1,130 ) Past service cost associated with multi-employer plan — — — 16,137 Actuarial loss arising from change in current assumptions on funding of future pension increases — — — 556 Benefits paid (344 ) (1 ) (345 ) (511 ) Impact of foreign exchange rate changes (2,098 ) (8 ) (2,106 ) (1,228 ) Balances – End of the period 17,258 95 17,353 29,412 Change in plan assets Balances – Beginning of the period 11,927 — 11,927 — Presentation of plan assets as of December 31, 2021 — — — 11,963 Remeasurement of plan assets (1,777 ) — (1,777 ) — Employer contributions 32 — 32 — Employee contributions 7 — 7 — Benefits paid (122 ) — (122 ) — Impact of foreign exchange rate changes (902 ) — (902 ) (36 ) Balances – End of the period 9,165 9,165 11,927 Net liability of the unfunded plans 7,574 95 7,669 12,749 Net liability of the funded plans 519 — 519 4,736 Net amount recognized as Employee future benefits 8,093 95 8,188 17,485 Amounts recognized: In net loss 181 6 187 (153 ) In other comprehensive loss (9,221 ) (8 ) (9,229 ) 2,408

Share capital, warrants and o_2

Share capital, warrants and other capital (Tables)	6 Months Ended
	Jun. 30, 2022
Disclosure of classes of share capital [abstract]
Summary of Fair Value of Warrants Assumptions Explanatory	The table presented below shows the inputs and assumptions applied to the Black-Scholes option pricing model in order to determine the fair value of these Placement agent warrants: Summary of Fair Value of Warrants Assumptions Explanatory Number of equivalent shares Market value per share price Weighted average exercise price Risk-free annual interest rate Expected volatility Expected life (years) Expected dividend yield ($) ($) (i) (ii) (iii) (iv) February 2021 Placement agent warrants – public offering 57,427 37.00 45.31 0.58734 % 119.18 % 4.99 0.00 % February 2021 Placement agent warrants – Underwriter Option 8,614 37.00 45.31 0.58544 % 119.57 % 4.98 0.00 % (i) Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the warrants. (ii) Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the warrants. (iii) Based upon time to expiry from the issuance date. (iv) The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future.
Summary of Warrants Exercise Transactions Explanatory	During the six-month period ended June 30, 2021, warrants were exercised as follows:: Summary of Warrants Exercise Transactions Explanatory Warrants exercised (number of underlying common shares) Exercise Price Aggregate proceeds to the Company September 2019 Investor warrants 80,000 $ 41.25 $ 3,300 February 2020 Investor warrants 69,565 30.00 2,087 July 2020 Investor warrants 841,822 11.25 9,471 July 2020 Placement Agent warrants 74,667 14.0625 1,050 August 2020 Investor warrants 303,595 11.75 3,567 August 2020 Placement Agent warrants 34,798 17.6015625 612 1,404,447 $ 20,087
Summary of Number and Weighted Average Exercise Prices of Share Options Explanatory	Summary of Number and Weighted Average Exercise Prices of Share Options Explanatory Six months ended June 30, 2022 Stock options Weighted average exercise DSUs (Number) ($) (Number) Balance – January 1, 2022 43,455 22.00 16,920 Granted 2,000 9.00 — Expired — — — Exercised — — — Balance – June 30, 2022 45,455 21.25 16,920 Year ended December 31, 2021 Stock options Weighted average exercise DSUs (Number) ($) (Number) Balance – January 1, 2021 20,256 36.00 6,920 Granted 23,200 10.50 11,200 Expired (1 ) 14,756.25 — Exercised — — (1,200 ) Balance – December 31, 2021 43,455 22.00 16,920
Summary of Assumptions to Determine Share-based Compensation Costs	The table below shows the assumptions, or weighted average parameters, applied to the Black-Scholes option pricing model in order to determine share-based compensation costs over the life of the awards. Summary of Assumptions to Determine Share-based Compensation Costs Six Months Ended Year Ended June 30, December 31 2022 2021 Expected dividend yield (a) 0.00 % 0.00 % Expected volatility (b) 115.80 % 115.80 % Risk-free annual interest rate (c) 1.23 % 1.23 % Expected life (years) (d) 5.71 5.71 Weighted average share price $ 0.42 $ 0.42 Weighted average exercise price $ 0.42 $ 0.42 Weighted average grant date fair value $ 0.35 $ 0.35 (a) The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future. (b) Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the stock options, as well as on future expectations. (c) Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the stock options. (d) Based upon historical data related to the exercise of stock options, on post-vesting employment terminations and on future expectations related to exercise behavior.

Supplemental disclosure of ca_2

Supplemental disclosure of cash flow information (Tables)	6 Months Ended
	Jun. 30, 2022
Summary of Changes in Operating Assets and Liabilities Explanatory	Summary of Changes in Operating Assets and Liabilities Explanatory Three months ended Six months ended June 30, June 30, 2022 2021 2022 2021 $ $ $ $ Changes in operating assets and liabilities: Trade and other receivables (255 ) (547 ) 220 103 Inventory — 1 (206 ) (39 ) Prepaid expenses and other current assets (1,471 ) 408 (759 ) 315 Payables and accrued liabilities (40 ) (430 ) 119 (315 ) Taxes payable — — — (129 ) Deferred revenues 1,001 3 1,008 1,230 Employee future benefits (97 ) (74 ) (118 ) (157 ) Changes in operating assets and liabilities (862 ) (639 ) 264 1,008

Net loss per share (Tables)

Net loss per share (Tables)	6 Months Ended
	Jun. 30, 2022
Summary of Earnings per Share Explanatory	The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders. Summary of Earnings per Share Explanatory Three months ended Six months ended June 30, June 30, 2022 2021 2022 2021 $ $ $ $ Net loss (4,216 ) (2,084 ) (6,856 ) (3,542 ) Basic weighted average number of shares outstanding 4,855,876 4,848,129 4,855,876 4,335,821 Net loss income per share (basic) (0.87 ) (0.43 ) (1.41 ) (0.82 ) Dilutive effect of stock options and DSUs — — — — Dilutive effect of warrants — — — — Diluted weighted average number of shares outstanding 4,855,876 4,848,129 4,855,876 4,335,821 Net loss per share (diluted) (0.87 ) (0.43 ) (1.41 ) (0.82 ) Items excluded from the calculation of diluted net loss per share because the exercise price was greater than the average market price of the common shares or due to their anti-dilutive effect Stock options and DSUs 62,375 37,176 62,375 37,176 Warrants 457,649 461,649 457,649 461,649

Commitments (Tables)

Commitments (Tables)	6 Months Ended
	Jun. 30, 2022
Summary of Finance Lease and Operating Lease by Lessee Explanatory	Summary of Finance Lease and Operating Lease by Lessee Explanatory Service and manufacturing R&D contracts TOTAL $ $ $ Less than 1 year 5,015 2,090 7,105 1 - 3 years 938 776 1,714 4 - 5 years 47 — 47 More than 5 years — — — Total 6,000 2,866 8,866
Summary of Research and Development and Revenue Related Milestone Payments Explanatory	Summary of Research and Development and Revenue Related Milestone Payments Explanatory Future potential R&D milestone payments Future potential revenue milestone payments TOTAL $ $ $ Less than 1 year 26 — 26 1 - 3 years 204 — 204 4 - 5 years 1,990 — 1,990 More than 5 years 6,830 39,302 46,132 Total 9,050 39,302 48,352

Summary of Detailed Information

Summary of Detailed Information about Restatement Explanatory (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
IfrsStatementLineItems [Line Items]
License fees	$ (206)	$ 492	$ 226	$ 1,016
Development service revenues	(77)	1,030	889	2,125
Research and development expenses	2,398	1,768	4,788	3,226
Net loss	(4,216)	(2,084)	(6,856)	(3,542)
Total comprehensive loss	$ 1,102	$ (3,178)	$ 1,248	$ (3,207)
Basic and diluted loss per share	$ (0.87)	$ (0.43)	$ (1.41)	$ (0.82)
Prepaid expenses and other current assets	$ 2,459	$ 4,375	$ 2,459	$ 4,375	$ 1,772
Current portion of deferred revenues	3,534	3,236	3,534	3,236	4,815
Deficit	$ (333,450)	(326,287)	$ (333,450)	(326,287)	$ (334,619)
Previously stated [member]
IfrsStatementLineItems [Line Items]
License fees		537		1,074
Development service revenues
Research and development expenses		738		1,101
Net loss		(2,039)		(3,484)
Total comprehensive loss		$ (3,133)		$ (3,149)
Basic and diluted loss per share		$ (0.42)		$ (0.72)
Prepaid expenses and other current assets		$ 3,308		$ 3,308
Current portion of deferred revenues		2,125		2,125
Deficit		(326,229)		(326,229)
Increase (decrease) due to corrections of prior period errors [member]
IfrsStatementLineItems [Line Items]
License fees		(45)		(58)
Development service revenues		1,030		2,125
Research and development expenses		1,030		2,125
Net loss		(45)		(58)
Total comprehensive loss		$ (45)		$ (58)
Basic and diluted loss per share		$ (0.01)		$ (0.01)
Prepaid expenses and other current assets		$ 1,067		$ 1,067
Current portion of deferred revenues		1,111		1,111
Deficit		$ (58)		$ (58)

Business overview (Details Narr

Business overview (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disclosure of detailed information about business combination [abstract]
License fees	$ 206	$ (492)	$ (226)	$ (1,016)
Development Services	$ 77	$ (1,030)	$ (889)	$ (2,125)

Summary of Revenue Explanatory

Summary of Revenue Explanatory (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021
IfrsStatementLineItems [Line Items]
Current	$ 3,534	$ 4,815	$ 3,236
Non-Current	2,617	1,493
Total	6,151	6,308
Novo Amendment [member]
IfrsStatementLineItems [Line Items]
Current	3,523	4,791
Non-Current	1,050	23
Total	4,573	4,814
CH License Agreement [member]
IfrsStatementLineItems [Line Items]
Current	11	24
Non-Current	1,440	1,334
Total	1,451	1,358
NK License Agreement [member]
IfrsStatementLineItems [Line Items]
Current
Non-Current	127	136
Total	$ 127	$ 136

Summary of Detailed Trade and O

Summary of Detailed Trade and Other Receivables Explanatory (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Trade accounts receivable (net of expected credit losses of $55 (December 31, 2021 – ($55)	$ 490	$ 877
Value-added tax	182	372
Grant receivable	179
Other	56	65
Trade and other receivables	$ 907	$ 1,314

Disclosure of Detailed Trade an

Disclosure of Detailed Trade and Other Receivables Explanatory (Details) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Trade accounts receivable, expected credit losses	$ 55	$ 55

Summary of Prepaid Expenses and

Summary of Prepaid Expenses and Other Current Assets Explanatory (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021
Prepaid insurance	$ 1,259	$ 421
Prepaid research and development	1,111	1,329
Other	89	22
Prepaid expenses and other current assets	$ 2,459	$ 1,772	$ 4,375

Summary of Detailed Informati_2

Summary of Detailed Information about Payables and Accrued Liabilities Explanatory (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Trade accounts payable	$ 938	$ 934
Salaries, employment taxes and benefits	120	531
Accrued research and development costs	995	596
Other accrued liabilities	582	611
Payables and accrued liabilities	$ 2,635	$ 2,672

Summary of Net Defined Benefit

Summary of Net Defined Benefit Liability Asset Explanatory (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Change in plan liabilities
Balances – Beginning of the period	$ 29,412	$ 15,435
Current service cost	38	65
Interest cost	149	88
Employee contributions	7
Actuarial gain arising from changes in financial assumptions	(9,802)	(1,130)
Past service cost associated with multi-employer plan		16,137
Actuarial loss arising from change in current assumptions on funding of future pension increases		556
Benefits paid	(345)	(511)
Impact of foreign exchange rate changes	(2,106)	(1,228)
Balances – End of the period	17,353	29,412
Change in plan assets
Balances – Beginning of the period	11,927
Presentation of plan assets as of December 31, 2021		11,963
Remeasurement of plan assets	(1,777)
Employer contributions	32
Benefits paid	(122)
Impact of foreign exchange rate changes	(902)	(36)
Balances – End of the period	9,165	11,927
Net liability of the unfunded plans	7,669	12,749
Net liability of the funded plans	519	4,736
Net amount recognized as Employee future benefits	8,188	17,485
Amounts recognized:
In net loss	187	(153)
In other comprehensive loss	(9,229)	2,408
Pension defined benefit plans [member]
Change in plan liabilities
Balances – Beginning of the period	29,313
Current service cost	33
Interest cost	149
Employee contributions	7
Actuarial gain arising from changes in financial assumptions	(9,802)
Past service cost associated with multi-employer plan
Actuarial loss arising from change in current assumptions on funding of future pension increases
Benefits paid	(344)
Impact of foreign exchange rate changes	(2,098)
Balances – End of the period	17,258	29,313
Change in plan assets
Balances – Beginning of the period	11,927
Presentation of plan assets as of December 31, 2021
Remeasurement of plan assets	(1,777)
Employer contributions	32
Benefits paid	(122)
Impact of foreign exchange rate changes	(902)
Balances – End of the period	9,165	11,927
Net liability of the unfunded plans	7,574
Net liability of the funded plans	519
Net amount recognized as Employee future benefits	8,093
Amounts recognized:
In net loss	181
In other comprehensive loss	(9,221)
Other benefit plans [member]
Change in plan liabilities
Balances – Beginning of the period	99
Current service cost	5
Interest cost
Employee contributions
Actuarial gain arising from changes in financial assumptions
Past service cost associated with multi-employer plan
Actuarial loss arising from change in current assumptions on funding of future pension increases
Benefits paid	(1)
Impact of foreign exchange rate changes	(8)
Balances – End of the period	95	99
Change in plan assets
Balances – Beginning of the period
Presentation of plan assets as of December 31, 2021
Remeasurement of plan assets
Employer contributions
Benefits paid
Impact of foreign exchange rate changes
Balances – End of the period
Net liability of the unfunded plans	95
Net liability of the funded plans
Net amount recognized as Employee future benefits	95
Amounts recognized:
In net loss	6
In other comprehensive loss	$ (8)

Employee future benefits (Detai

Employee future benefits (Details Narrative)	Jun. 30, 2022	Dec. 31, 2021
Pension defined benefit plans [member]
IfrsStatementLineItems [Line Items]
Defined benefit obligation, discount rate	1.10%	3.25%

Summary of Fair Value of Warran

Summary of Fair Value of Warrants Assumptions Explanatory (Details) - $ / shares		6 Months Ended	12 Months Ended
		Jun. 30, 2022	Dec. 31, 2021
IfrsStatementLineItems [Line Items]
Market value per share price		$ 0.42	$ 0.42
Risk-free annual interest rate	[1]	1.23%	1.23%
Expected volatility	[2]	115.80%	115.80%
Expected dividend yield	[3]	0%	0%
February 2021 Placement Agent Warrants Underwriter Option [member]
IfrsStatementLineItems [Line Items]
Number of equivalent shares		57,427
Market value per share price		$ 37
Weighted average exercise price		$ 45.31
Risk-free annual interest rate	[4]	0.58734%
Expected volatility	[5]	119.18%
Expected life (years)	[6]	4 years 11 months 26 days
Expected dividend yield	[7]	0%
February 2021 Placement Agent Warrants Public Offering [member]
IfrsStatementLineItems [Line Items]
Number of equivalent shares		8,614
Market value per share price		$ 37
Weighted average exercise price		$ 45.31
Risk-free annual interest rate	[4]	0.58544%
Expected volatility	[5]	119.57%
Expected life (years)	[6]	4 years 11 months 23 days
Expected dividend yield	[7]	0%
[1]Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the stock options.[2]Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the stock options, as well as on future expectations.[3]The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future.[4]Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the warrants.[5]Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the warrants.[6]Based upon time to expiry from the issuance date.[7]The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future.

Summary of Warrants Exercise Tr

Summary of Warrants Exercise Transactions Explanatory (Details) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2021 USD ($) shares $ / shares	Jun. 30, 2022 $ / shares	Dec. 31, 2021 $ / shares	Dec. 31, 2020 $ / shares
IfrsStatementLineItems [Line Items]
Number of share options exercised in share-based payment arrangement | shares	1,404,447
Exercise Price | $ / shares		$ 21.25	$ 22	$ 36
Proceeds from exercise of options | $	$ 20,087
September 2019 Investor Warrants [member]
IfrsStatementLineItems [Line Items]
Number of share options exercised in share-based payment arrangement | shares	80,000
Exercise Price | $ / shares	$ 41.25
Proceeds from exercise of options | $	$ 3,300
February 2020 Investor Warrants [member]
IfrsStatementLineItems [Line Items]
Number of share options exercised in share-based payment arrangement | shares	69,565
Exercise Price | $ / shares	$ 30
Proceeds from exercise of options | $	$ 2,087
July 2020 Investor Warrants [member]
IfrsStatementLineItems [Line Items]
Number of share options exercised in share-based payment arrangement | shares	841,822
Exercise Price | $ / shares	$ 11.25
Proceeds from exercise of options | $	$ 9,471
July 2020 Placement Agent Warrants [member]
IfrsStatementLineItems [Line Items]
Number of share options exercised in share-based payment arrangement | shares	74,667
Exercise Price | $ / shares	$ 14.0625
Proceeds from exercise of options | $	$ 1,050
August 2020 Investor Warrants [member]
IfrsStatementLineItems [Line Items]
Number of share options exercised in share-based payment arrangement | shares	303,595
Exercise Price | $ / shares	$ 11.75
Proceeds from exercise of options | $	$ 3,567
August 2020 Placement Agent Warrants [member]
IfrsStatementLineItems [Line Items]
Number of share options exercised in share-based payment arrangement | shares	34,798
Exercise Price | $ / shares	$ 17.6015625
Proceeds from exercise of options | $	$ 612

Summary of Number and Weighted

Summary of Number and Weighted Average Exercise Prices of Share Options Explanatory (Details)	6 Months Ended		12 Months Ended
	Jun. 30, 2022 shares $ / shares	Jun. 30, 2021 shares $ / shares	Dec. 31, 2021 shares $ / shares
IfrsStatementLineItems [Line Items]
Weighted average exercise price, balance beginning | $ / shares	$ 22	$ 36	$ 36
Weighted average exercise price, granted | $ / shares	9		10.50
Weighted average exercise price, expired | $ / shares			14,756.25
Shares, exercised		(1,404,447)
Weighted average exercise price, exercised | $ / shares
Weighted average exercise price, balance ending | $ / shares	$ 21.25		$ 22
Employee Stock Option USD [member]
IfrsStatementLineItems [Line Items]
Shares, balance beginning	43,455	20,256	20,256
Shares, granted	2,000		23,200
Shares, expired			(1)
Shares, exercised
Shares, balance ending	45,455		43,455
Deferred Stock Units DSU [member]
IfrsStatementLineItems [Line Items]
Shares, balance beginning	16,920	6,920	6,920
Shares, granted			11,200
Shares, expired
Shares, exercised			(1,200)
Shares, balance ending	16,920		16,920

Summary of Assumptions to Deter

Summary of Assumptions to Determine Share-based Compensation Costs (Details) - $ / shares		6 Months Ended	12 Months Ended
		Jun. 30, 2022	Dec. 31, 2021
Disclosure of classes of share capital [abstract]
Expected dividend yield	[1]	0%	0%
Expected volatility	[2]	115.80%	115.80%
Risk-free annual interest rate	[3]	1.23%	1.23%
Expected life (years)	[4]	5 years 8 months 15 days	5 years 8 months 15 days
Weighted average share price		$ 0.42	$ 0.42
Weighted average exercise price		0.42	0.42
Weighted average grant date fair value		$ 0.35	$ 0.35
[1]The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future.[2]Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the stock options, as well as on future expectations.[3]Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the stock options.[4]Based upon historical data related to the exercise of stock options, on post-vesting employment terminations and on future expectations related to exercise behavior.

Share capital, warrants and o_3

Share capital, warrants and other capital (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Feb. 22, 2021	Feb. 19, 2021
Warrants [member]
IfrsStatementLineItems [Line Items]
Proceeds from issuing common shares	$ 34,200
Cash transaction costs	3,221
Warrant liability	$ 1,897
Underwriter Option [member]
IfrsStatementLineItems [Line Items]
Number of common shares issued, shares	8,614
Proceeds from issuing common shares	$ 4,461
Option to purchase common stock	123,058
Public Offering [member]
IfrsStatementLineItems [Line Items]
Number of common shares issued, shares		820,390
Share price		$ 36.25
Proceeds from issuing common shares		$ 29,739
Placement agent fees and other offering expenses		$ 2,837
Public Offering [member] | Warrants [member]
IfrsStatementLineItems [Line Items]
Warrants Issued		57,427
Warrants exercise price		$ 45.3125
Warrants expiry date		Feb. 17, 2026
Underwriter Option [member]
IfrsStatementLineItems [Line Items]
Share price		$ 36.25
Option to purchase common stock		123,058

Summary of Changes in Operating

Summary of Changes in Operating Assets and Liabilities Explanatory (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Trade and other receivables	$ (255)	$ (547)	$ 220	$ 103
Inventory		1	(206)	(39)
Prepaid expenses and other current assets	(1,471)	408	(759)	315
Payables and accrued liabilities	(40)	(430)	119	(315)
Taxes payable				(129)
Deferred revenues	1,001	3	1,008	1,230
Employee future benefits	(97)	(74)	(118)	(157)
Changes in operating assets and liabilities	$ (862)	$ (639)	$ 264	$ 1,008

Summary of Earnings per Share E

Summary of Earnings per Share Explanatory (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Net loss	$ (4,216)	$ (2,084)	$ (6,856)	$ (3,542)
Basic weighted average number of shares outstanding	4,855,876	4,848,129	4,855,876	4,335,821
Net loss income per share (basic)	$ (0.87)	$ (0.43)	$ (1.41)	$ (0.82)
Dilutive effect of stock options and DSUs
Dilutive effect of warrants
Diluted weighted average number of shares outstanding	4,855,876	4,848,129	4,855,876	4,335,821
Net loss per share (diluted)	$ (0.87)	$ (0.43)	$ (1.41)	$ (0.82)
Stock options and DSUs	62,375	37,176	62,375	37,176
Warrants	457,649	461,649	457,649	461,649

Summary of Finance Lease and Op

Summary of Finance Lease and Operating Lease by Lessee Explanatory (Details) $ in Thousands	Jun. 30, 2022 USD ($)
IfrsStatementLineItems [Line Items]
Minimum lease payments, net	$ 8,866
Services and manufacturing [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net	6,000
R&D contracts [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net	2,866
Less than 1 Year [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net	7,105
Less than 1 Year [member] | Services and manufacturing [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net	5,015
Less than 1 Year [member] | R&D contracts [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net	2,090
1 - 3 Years [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net	1,714
1 - 3 Years [member] | Services and manufacturing [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net	938
1 - 3 Years [member] | R&D contracts [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net	776
4 - 5 Years [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net	47
4 - 5 Years [member] | Services and manufacturing [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net	47
4 - 5 Years [member] | R&D contracts [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net
More than 5 Years [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net
More than 5 Years [member] | Services and manufacturing [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net
More than 5 Years [member] | R&D contracts [member]
IfrsStatementLineItems [Line Items]
Minimum lease payments, net

Summary of Research and Develop

Summary of Research and Development and Revenue Related Milestone Payments Explanatory (Details) $ in Thousands	Jun. 30, 2022 USD ($)
IfrsStatementLineItems [Line Items]
Milestone payments	$ 48,352
R&D milestone payments [member]
IfrsStatementLineItems [Line Items]
Milestone payments	9,050
Revenue milestone payments [member]
IfrsStatementLineItems [Line Items]
Milestone payments	39,302
Less than 1 Year [member]
IfrsStatementLineItems [Line Items]
Milestone payments	26
Less than 1 Year [member] | R&D milestone payments [member]
IfrsStatementLineItems [Line Items]
Milestone payments	26
Less than 1 Year [member] | Revenue milestone payments [member]
IfrsStatementLineItems [Line Items]
Milestone payments
1 - 3 Years [member]
IfrsStatementLineItems [Line Items]
Milestone payments	204
1 - 3 Years [member] | R&D milestone payments [member]
IfrsStatementLineItems [Line Items]
Milestone payments	204
1 - 3 Years [member] | Revenue milestone payments [member]
IfrsStatementLineItems [Line Items]
Milestone payments
4 - 5 Years [member]
IfrsStatementLineItems [Line Items]
Milestone payments	1,990
4 - 5 Years [member] | R&D milestone payments [member]
IfrsStatementLineItems [Line Items]
Milestone payments	1,990
4 - 5 Years [member] | Revenue milestone payments [member]
IfrsStatementLineItems [Line Items]
Milestone payments
More than 5 Years [member]
IfrsStatementLineItems [Line Items]
Milestone payments	46,132
More than 5 Years [member] | R&D milestone payments [member]
IfrsStatementLineItems [Line Items]
Milestone payments	6,830
More than 5 Years [member] | Revenue milestone payments [member]
IfrsStatementLineItems [Line Items]
Milestone payments	$ 39,302

Commitments (Details Narrative)

Commitments (Details Narrative) $ in Thousands, € in Millions, £ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2022 EUR (€)	Jun. 30, 2022 GBP (£)
IfrsStatementLineItems [Line Items]
Potential milestone payments description	the Company expects to pay $9,050 including $6,804 (€6.5 million), and $1,396 (£1.2 million) and $850 USD, in R&D milestone payments and up to $39,302, including $28,785 (€27.6 million); $1,517 (£1.3 million) and $9,000 USD, in revenue related milestone payments.	the Company expects to pay $9,050 including $6,804 (€6.5 million), and $1,396 (£1.2 million) and $850 USD, in R&D milestone payments and up to $39,302, including $28,785 (€27.6 million); $1,517 (£1.3 million) and $9,000 USD, in revenue related milestone payments.	the Company expects to pay $9,050 including $6,804 (€6.5 million), and $1,396 (£1.2 million) and $850 USD, in R&D milestone payments and up to $39,302, including $28,785 (€27.6 million); $1,517 (£1.3 million) and $9,000 USD, in revenue related milestone payments.
Research and Development Contracts [Member]
IfrsStatementLineItems [Line Items]
Potential milestone payments	$ 9,050	€ 6.5	£ 1.2
R&D milestone payments [member]
IfrsStatementLineItems [Line Items]
Potential milestone payments	39,302	€ 27.6	£ 1.3
Revenue milestone payments [member]
IfrsStatementLineItems [Line Items]
Potential milestone payments	$ 9,000